Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia Sep 13, 2022
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference Sep 12, 2022
Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022 Aug 2, 2022
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia Jul 27, 2022
Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program May 23, 2022
